Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Vanilloid receptor | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | DNA topoisomerase 2 homolog | 0.1352 | 0.1747 | 1 |
Trypanosoma cruzi | mitochondrial DNA topoisomerase II, putative | 0.3344 | 0.5455 | 1 |
Mycobacterium leprae | Probable DNA gyrase (subunit B) GyrB (DNA topoisomerase (ATP-hydrolysing)) (DNA topoisomerase II) (Type II DNA topoisomerase) | 0.1992 | 0.2938 | 1 |
Entamoeba histolytica | DNA topoisomerase II, putative | 0.1352 | 0.1747 | 1 |
Giardia lamblia | DNA topoisomerase II | 0.117 | 0.1409 | 1 |
Plasmodium falciparum | DNA gyrase subunit B | 0.5785 | 1 | 1 |
Toxoplasma gondii | ATPase/histidine kinase/DNA gyrase B/HSP90 domain-containing protein | 0.3344 | 0.5455 | 1 |
Treponema pallidum | DNA gyrase, subunit B (gyrB) | 0.5785 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | DNA gyrase, topoisomerase II, B subunit, GyrB | 0.5785 | 1 | 1 |
Plasmodium vivax | DNA gyrase subunit B, putative | 0.5785 | 1 | 1 |
Leishmania major | DNA topoisomerase ii | 0.0938 | 0.0977 | 0.1791 |
Brugia malayi | DNA topoisomerase II, alpha isozyme | 0.1352 | 0.1747 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0938 | 0.0977 | 0.5592 |
Mycobacterium tuberculosis | DNA gyrase (subunit B) GyrB (DNA topoisomerase (ATP-hydrolysing)) (DNA topoisomerase II) (type II DNA topoisomerase) | 0.5785 | 1 | 0.5 |
Plasmodium vivax | DNA topoisomerase II, putative | 0.1352 | 0.1747 | 0.1747 |
Brugia malayi | DNA gyrase/topoisomerase IV, A subunit family protein | 0.1352 | 0.1747 | 1 |
Schistosoma mansoni | DNA topoisomerase II | 0.1352 | 0.1747 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0938 | 0.0977 | 0.5592 |
Mycobacterium ulcerans | DNA gyrase subunit B | 0.5785 | 1 | 1 |
Onchocerca volvulus | DNA topoisomerase 2 homolog | 0.1352 | 0.1747 | 1 |
Leishmania major | mitochondrial DNA topoisomerase II | 0.3344 | 0.5455 | 1 |
Loa Loa (eye worm) | TOPoisomerase family member | 0.1352 | 0.1747 | 1 |
Plasmodium falciparum | DNA topoisomerase 2 | 0.1352 | 0.1747 | 0.1747 |
Trypanosoma cruzi | mitochondrial DNA topoisomerase II, putative | 0.3344 | 0.5455 | 1 |
Onchocerca volvulus | Putative DNA topoisomerase 2, mitochondrial | 0.1352 | 0.1747 | 1 |
Echinococcus granulosus | DNA topoisomerase 2 alpha | 0.1352 | 0.1747 | 1 |
Trypanosoma brucei | DNA topoisomerase II beta, putative | 0.0938 | 0.0977 | 0.1791 |
Trypanosoma brucei | DNA topoisomerase II alpha, putative | 0.0938 | 0.0977 | 0.1791 |
Trypanosoma brucei | DNA topoisomerase ii | 0.3344 | 0.5455 | 1 |
Trypanosoma cruzi | DNA topoisomerase II, putative | 0.0938 | 0.0977 | 0.1791 |
Trichomonas vaginalis | DNA topoisomerase II, putative | 0.1352 | 0.1747 | 1 |
Trypanosoma cruzi | DNA topoisomerase II, putative | 0.0938 | 0.0977 | 0.1791 |
Chlamydia trachomatis | DNA gyrase subunit B | 0.3793 | 0.6292 | 0.6292 |
Brugia malayi | Probable DNA topoisomerase II | 0.1352 | 0.1747 | 1 |
Toxoplasma gondii | DNA topoisomerase 2, putative | 0.1352 | 0.1747 | 0.3202 |
Echinococcus multilocularis | DNA topoisomerase 2 alpha | 0.1352 | 0.1747 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | Agonist activity at rat TRPV1 expressed in CHO cells assessed as effect on pH 5 acid-induced 45Ca2+ influx by FLIPR assay | ChEMBL. | 18722118 | |
Activity (functional) | Agonist activity at rat TRPV1 expressed in CHO cells assessed as effect on capsaicin-induced 45Ca2+ influx by FLIPR assay | ChEMBL. | 18722118 | |
IC50 (functional) | = 210 nM | Antagonist activity at rat TRPV1 expressed in CHO cells assessed as inhibition of capsaicin-induced 45Ca2+ influx by FLIPR assay | ChEMBL. | 18722118 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.